Malignant mesothelioma research, a priority of the Manhattan pharmaceutical company, INNOVIVE Pharmaceuticals, Inc., has commenced Phase I testing of its new drug INNO-305. The drug will be tested on patients with non-small cell lung cancer, leukemia, and mesothelioma. The cancer treatment drug will be distributed in fixed doses to patients with solid tumors and hematologic malignancies to determine its safety and effectiveness as a
new treatment for mesothelioma and other malignant cancers.
Doctor David A. Scheinberg, one of the creator's of INNO-305, observed that, in pre-trial testing on patients with non-small cell lung cancer, leukemia, and mesothelioma, the cancer treatment drug performed well and gave positive indications that that it may turn out to be a viable cancer therapeutic.
For researchers, INNO-305 is unique among its class of WT1 peptide vaccines because it has the ability to stimulate both CD4 and CD8 T-cells. There is speculation that by stimulating both of these T-cells, the body may be able to mount a more effective defense against cancer cells.
This study, for a potential new treatment for mesothelioma and other cancers, is being conducted at the Memorial Sloan Kettering Cancer Center, in New York, under the supervision of Doctors Peter Maslak and Lee Krug.
To find out more about this ongoing clinical trial please follow this link to visit the
Memorial Sloan Kettering Cancer Center.
Asbestos is the only known cause of mesothelioma, a virulent cancer that occurs primarily in the lining of the lungs and the abdomen. Mesothelioma typically occurs at least fifteen years after a person' first exposure to Asbestos. Asbestos fibers are microscopic and exposure can occur without a worker's knowledge even if protective gear is worn. Mesothelioma occurs not only in people working directly with Asbestos products but also in bystanders and family members exposed to Asbestos dust.
Malignant mesothelioma research needs to be a priority in order to find a cure for this rare, but deadly disease.
